Oct, 24 2025
Learn how rasagiline, a selective MAO‑B inhibitor, can improve symptoms of drug‑induced Parkinsonism, including evidence, dosing, safety, and practical tips.
MAO‑B Inhibitor Overview
When talking about MAO‑B inhibitor, a class of drugs that block the enzyme monoamine oxidase B, reducing the breakdown of dopamine and other neurotransmitters. Also known as MAO‑B blocker, it helps keep dopamine levels higher in the brain.
One of the biggest reasons patients and doctors care about this class is its link to Parkinson's disease, a neurodegenerative disorder marked by low dopamine and motor symptoms. The relationship is clear: MAO‑B inhibitor reduces dopamine breakdown, which in turn eases the motor challenges of Parkinson's disease. Two of the most common drugs you’ll hear about are Selegiline, the first FDA‑approved MAO‑B inhibitor, often used early in Parkinson's treatment and Rasagiline, a newer, once‑daily option with a slightly different side‑effect profile. Both work by inhibiting the MAO‑B enzyme, which otherwise converts dopamine into inactive metabolites.
How MAO‑B Inhibitors Work and What to Expect
Mechanistically, an MAO‑B inhibitor binds to the active site of the monoamine oxidase B enzyme, preventing it from oxidizing dopamine. This simple action creates a cascade: higher dopamine levels improve motor control, and patients often report smoother movement and less “off” time. Because dopamine also influences mood, some clinicians use low‑dose MAO‑B inhibitors to boost mood in early Parkinson's without triggering the dietary restrictions seen with non‑selective MAO inhibitors.
Safety matters, too. While MAO‑B inhibitors are generally well‑tolerated, they can interact with certain antidepressants, stimulants, or foods high in tyramine if the dose is high enough to affect MAO‑A. Knowing the difference between selective MAO‑B inhibition and non‑selective inhibition helps avoid dangerous hypertensive crises. Recent research shows that using rasagiline at therapeutic doses rarely requires strict dietary limits, making it a convenient choice for many patients.
Beyond Parkinson's, MAO‑B inhibitors have been explored for cognitive decline in Alzheimer's disease and even for certain depressive disorders where dopamine loss plays a role. The growing body of evidence means the drug class is expanding its reach, and clinicians are paying more attention to individual patient profiles when picking selegiline versus rasagiline.
Below you’ll find a curated set of articles that dive deeper into specific drugs, side‑effect management, diet considerations, and the latest clinical guidelines. Whether you’re a patient looking for practical tips or a caregiver seeking clear explanations, the collection ahead offers focused insight on every angle of MAO‑B inhibition.